Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

被引：4
|
作者：
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Stefaniak, V. [10 ]
Lin, Y. [10 ]
Wang, S. [11 ]
Zhang, W. [11 ]
Sun, L. [11 ]
Zhang, Y. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[3] Peking Univ Canc Hosp, Beijing, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Pulm Med Dept, Shanghai, Peoples R China
[6] Zhengzhou Univ, Henan Prov Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[10] Eli Lilly & Co, Indianapolis, IN 46285 USA
[11] Innovent Biol Inc, Suzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4MO
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
    Shen, L.
    Lu, Z-H.
    Wang, J-Y.
    Shu, Y-Q.
    Kong, L.
    Yang, L.
    Wang, B-H.
    Wang, Z-W.
    Ji, Y-H.
    Cao, G-C.
    Liu, H.
    Cui, T-J.
    Li, N.
    Qiu, W-S.
    Ma, Z.
    Chen, Y-L.
    Li, H-Y.
    Sun, X.
    Wang, Y.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1330 - S1330
  • [22] First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
    Planchard, D.
    Poltoratskiy, A.
    Kim, S-W.
    Kim, T. M.
    Yanagitani, N.
    Kagamu, H.
    Feng, P-H.
    Hughes, B.
    Yang, T-Y.
    Yang, J. C-H.
    Lee, C. K.
    Karaseva, N.
    Mitchell, P.
    Tambo, Y.
    Monterroso, E. Armenteros
    Todd, A.
    Sahasrabudhe, A.
    Janne, P. A.
    Kobayashi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1692 - S1693
  • [23] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic nonesmall cell lung cancer (mNSCLC)
    Lu, S.
    Vynnychenko, O.
    Kulyaba, Y.
    Kuchava, V.
    Ibrahim, A.
    Moiseenko, F. V.
    Arslan, C.
    Nguyen, D. T.
    Zhang, M.
    Petrovic, M. D.
    Cicin, I.
    Bibichadze, K.
    Cil, T.
    Cornfeld, M.
    Tian, C.
    Munteanu, M.
    Sette, C. V. D. M.
    Bondarenko, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1633 - S1634
  • [25] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [26] Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN)
    Besse, Benjamin
    Le Moulec, Sylvestre
    Senellart, Helene
    Mazieres, Julien
    Barlesi, Fabrice
    Dansin, Eric
    Robinet, Gilles
    Perol, Maurice
    Moro-Sibilot, Denis
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).
    Wang, Jie
    Yu, Xinmin
    Lu, Shun
    Hu, Yanping
    Sun, Yuping
    Wang, Zhijie
    Zhao, Jun
    Yu, Yan
    Hu, Chunhong
    Yang, Kunyu
    Feng, Guosheng
    Ying, Kejing
    Zhuang, Wu
    Zhou, Jianying
    Wu, Jingxun
    Wu, Yanjie
    Lin, Xiao
    Liang, Liang
    Yang, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Corral, Jesus
    Melemed, Symantha
    John, William
    Chouaki, Nadia
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2895 - +
  • [29] ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma
    Shen, Lin
    Lu, Zhihao
    Xu, Linxinyu
    Wang, Yan
    Zhou, Hui
    Liu, Ying
    CANCER RESEARCH, 2019, 79 (13)
  • [30] CIS-PLATINUM, PEMETREXED AND BEVACIZUMAB (CPBEV) AS FIRST-LINE THERAPY FOR LOCALLY ADVANCED OR METASTATIC ADENOCARCINOMA OF THE LUNG: PRELIMINARY DATA OF SAFETY AND EFFICACY OF A PHASE II STUDY
    Bordonaro, R.
    Soto-Parra, H.
    Nacci, A.
    Latteri, F.
    Rizzo, P.
    Cordio, S.
    Salice, P.
    Sambataro, D.
    Potenza, E.
    Cinieri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S94 - S94
12345